カボザンチニブ (20 mg) とニボルマブの初期投与量の効果と安全性
Tomokazu Sazuka1, Yuri Watanabe1, Fumiya Yokochi1
1Department of Urology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
Japanese journal of clinical oncology
|August 29, 2025
まとめ
腎臓細胞癌患者におけるカボザンチニブ (20 mg) の初期投与量は,標準投与量と同様の有効性を示した. このアプローチは,耐受性,特に肝臓機能を改善することができます.
科学分野:
- 腫瘍学
- 薬理学について
- 臨床医学
背景:
- 腎臓細胞癌 (RCC) の全身治療には,しばしば副作用の管理のために投与量調整が必要である.
- カボザンチニブとニボルマブ (C+N) の初期投与量を減少させた証拠は限られている.
- RCC治療における用量調整の必要性には,患者特有の要因が影響する.
研究 の 目的:
- カボザンチニブ (20 mg) をニボルマブと併用してRCCの有効性と安全性を評価する.
- カボザンチニブを標準の開始用量と比較して,C+N療法を受けた患者のアウトカムを比較する.
- 副作用,特に肝臓機能障害に対する投与量減少の影響を評価する.
主な方法:
- C+Nで治療されたRCC患者の単一機関のデータを遡及分析した.
- カボザンチニブ (20 mgまたは40 mg) の開始用量は,患者の特徴に基づいて,多学科チームによって決定されます.
- ニボルマブの投与量とスケジュールは一定であり,有効性と有害事象は体系的に調査された.
主要な成果:
- 20 mgカボザンチニブ群では71%で,40 mg群では78%でした.
- 無進行生存率,全生存率,全生存率/重度の有害事象の有意な差異は認められなかった.
- 標準投与群 (61%) と比較して,低用量群で肝機能障害の発生率が著しく低下した.
結論:
- 20 mgのカボザンチニブをC+N療法で投与すると,標準の40 mgの投与量と同様の効果が得られます.
- 標準投与で治療を開始することを躊躇している患者にとって,初期投与量を減らすことが有効な選択肢である.
- 肝臓に関連する有害事象を軽減する潜在的利点を示しています.
さらに関連する動画
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
関連する概念動画
01:11Renal Failure: Dose Adjustments
152
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
152
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:06Renal Drug Clearance: Overview
325
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
325
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
267
Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
267
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K